{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-139402","form_type":"8-K","ticker":"SLNO","cik":"0001484565","company_name":"SOLENO THERAPEUTICS INC","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.003871+00:00","generated_at":"2026-06-15T08:50:10.948331+00:00","sec_items":["2.02","9.01","3.02"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Soleno completes PWS trial enrollment, gets $10M; Q1 net loss $8.4M","bullets":["Enrollment completed in randomized withdrawal period of Study C602 for DCCR in Prader-Willi syndrome; top-line data expected Q3 2023.","Received $10M from closing of December 2022 securities purchase agreement with Nantahala, Abingworth, Vivo Capital; warrants for 22.6M shares issued.","Cash and equivalents $7.9M at March 31, 2023; plus $10M received, expected to fund through top-line data.","Net loss $8.4M ($0.88 per share) vs $5.7M ($1.07) in Q1 2022; R&D expenses $5.3M vs $4.0M."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-139402","json":"https://secwatch.observer/filing/0001193125-23-139402.json","markdown":"https://secwatch.observer/filing/0001193125-23-139402.md","text":"https://secwatch.observer/filing/0001193125-23-139402.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1484565/000119312523139402/0001193125-23-139402-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1484565/000119312523139402/d421828d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T08:50:10.948331+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}